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INTRODUCTION
There are many different situations in
obstetrics where there is the need for labor
induction in women with unripe cervices. This
indication stems from a situation where the
continuation of pregnancy may be life-threat-
ening for the mother and/or fetus. Such in-
duction is frequently prolonged, exhausting
and very often unsuccessful, resulting in a
cesarean section.1-4
Among the pharmacological agents used
for labor induction, oxytocin and prosta-
glandins are the most common. Several stud-
ies have shown that continuous intravenous
infusion of oxytocin is less efficient, particu-
larly when there are unfavorable cervical con-
ditions, leading frequently to a cesarean sec-
tion, because of induction failure.2,4,5 In such
cases, another pharmacological agent, perhaps
a prostaglandin, should be used to favor cer-
vical ripening, at least initially.
Several studies have been performed, es-
pecially in developed countries, using pros-
taglandin E2 (dinoprostone) gel for cervical
ripening and labor induction, particularly in
cases where the Bishop Index6 is lower than
seven, in which its effectiveness was shown.
However, the widespread use of this drug is
limited because of its high cost and thermal
instability, which leads to difficult storage, plus
the occasional need to use oxytocin after cer-
vical ripening.7,8 In Brazil, this drug is not at
present being marketed.
Misoprostol (Cytotec®), a synthetic E1
methyl analog prostaglandin, is at present re-
ceiving more attention as a cervical modify-
ing agent and labor inductor, as it has the ad-
vantages of low cost, stability in relation to
temperature, easy handling and storage, and
also easy administration (vaginal or endocer-
vical).8-10 However, there is still a need to bet-
ter establish its safety so as to avoid hypersti-
mulation syndrome, which could result in
undesirable consequences for the newborn.
During the last few years, many studies
have been carried out on live fetus pregnan-
cies, to establish the best dose, administration
route and interval between doses for this cer-
vical ripening and labor induction drug and
compare it to oxytocin and dinoprostone.8,11,13
A meta-analysis performed in 1998 concluded
that vaginal misoprostol seems to be more ef-
fective for cervical ripening and labor induc-
tion than the conventional methods. How-
ever, it emphasized the need for complemen-
tary studies in order to achieve safer results in
relation to hyperstimulation syndrome and
perinatal results.14
According to the published studies, the
vaginal dose of misoprostol that has shown
greatest safety and efficiency for the mother
and newborn is 25 µg at 4-6 hourly inter-
vals.1,12,17 In fact, a recent study on the phar-
macokinetics of this drug showed that its se-
rum levels, after vaginal administration, re-
main stable for at least 4 hours, suggesting that
the ideal time interval between doses should
be greater than 4 hours.18
The incidence of cesarean deliveries is quite
high in Brazil. Some of them take place be-
cause of elective anticipation due to maternal
and/or fetal complications that are associated
with a high level of unsuccessful oxytocin in-
duction.19 In view of this, a randomized con-
trolled trial was proposed, in order to study the
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safety and effectiveness of vaginal misoprostol
given at four-hourly intervals for cervical rip-
ening and labor induction, in comparison with
oxytocin infusion, in pregnant women with
unripe cervices and live fetuses.
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METHODS
This was a randomized controlled clini-
cal trial. The sample, 210 pregnant women
requiring labor induction for any clinical and/
or obstetric reason, was selected between No-
vember 1998 and December 2000. The in-
clusion criteria were: medical indication for
labor induction; singleton gestation; gestation
age greater than 36 weeks; vertex presentation,
intact membranes; Bishop Index less than 6;
no labor occurring; and normal fetal heart rate.
The exclusion criteria were: pelvic dystocia;
estimated fetal weight greater than 4,000 g or
evidence of cephalopelvic disproportion; pla-
centa previa or any unexplained vaginal bleed-
ing; parity > 5; fetal malformation; previous
uterine scar; any situation when vaginal de-
livery was not indicated; and any contraindi-
cation to the use of misoprostol.
Sample size was calculated on the basis of
the results from a previous study using
misoprostol and oxytocin with the same ob-
jective.2 Using an alpha error of 0.01 and a
beta error of 0.05, the size of the sample was
estimated as 105 women for each group.
After being interviewed, the women who
met the eligibility criteria were invited to vol-
untarily participate in the study. Those who
accepted were carefully informed of the aims
and procedures of the study and then asked
to sign the informed consent form. Follow-
ing this, the fetal heart rate was monitored to
ensure fetal wellbeing before the onset of in-
duction. The random allocation procedure
was determined by opening a sequentially
numbered envelope, thereby determining
whether that woman should receive either
misoprostol or oxytocin. This random se-
quence was generated by computer and the
investigator was unaware of the sequence.
For women receiving misoprostol, 25 µg
were administered in the posterior fornix of the
vagina. The dose was repeated every 4 hours,
until a pattern of at least 3 contractions every
10 minutes was obtained. The maximum dose
was 200 µg. If this contraction pattern had not
been reached by four hours after the adminis-
tration of the eighth dose, induction was con-
sidered to have failed. After the ideal pattern of
contractions was reached, misoprostol was no
longer administered.
For the women in the oxytocin group, an
intravenous infusion of 2 mU/min was used,
which was doubled at 30-minute intervals
until the appropriate contraction pattern was
obtained. The infusion dose was increased to
a maximum of 20 mU/min, at which point it
was then maintained constant. If the contrac-
tion pattern had not been induced by the time
that 15 IU of oxytocin had been infused, the
induction was also considered to have failed.
Even after the ideal pattern was reached, oxy-
tocin flow was continued.
As soon as the patients presented the de-
sired contraction rate, monitoring of fetal
heart rate and intrapartum uterine activity was
performed. Amniotomy was carried out when
the Bishop Index was greater than 7 and cer-
vical dilation was greater than 6 cm.
In cases of tachysystole (6 or more con-
tractions every 10 minutes) and uterine
hypertonus/hypersystole (uterine contraction
with a duration of 2 minutes or more), and in
the absence of altered fetal heart rate moni-
toring, the reversion of such alterations was
done by means of the usual procedures and, if
necessary, tocolysis was used (terbutaline, 0.05
mg intravenously). In the cases where there
was no reversion of the abovementioned al-
terations, or if hyperstimulation syndrome
(tachysystole or uterine hypertonus/
hypersystole with abnormal fetal heart rate)
or fetal hypoxia (thick meconium and/or fe-
tal monitoring alteration) were also present,
induction was interrupted and a cesarean sec-
tion was performed.
For data analysis, the comparability of
the groups was initially evaluated through the
distribution of control variables, in order to
check the randomization process. To verify
the statistical significance of the differences
between the groups, the chi-squared and Stu-
dent t tests were used respectively for
categorial or continuous variables. To evalu-
ate Bishop Index changes, the latent period
(time from the beginning of induction to the
onset of labor) and the time from induction
to vaginal delivery, survival analysis was used.
The statistical significance was evaluated via
the Kaplan-Meyer method, through the log
rank test. For the main dependent variable
(delivery type) and variables related to safety,
the risk ratio and their corresponding 95%
confidence intervals (CI) were calculated.
Finally, for delivery type alone, the number
needed to treat (NNT) and its 95% CI was
also estimated. The value of statistical sig-
nificance adopted was 5%.
This study received approval from the
Institutional Review Board of the partici-
pating institution.
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
RESULTS
Out of the total of 210 women, 105 were
randomly allocated to the use of misoprostol
and 105 to oxytocin. In order to demonstrate
the randomization process for the groups, the
results from the control variables are presented.
No significant differences between the groups
concerning age, parity, race, marital status, fam-
ily income, initial Bishop Index and number
of prenatal visits were observed. The most com-
mon indication for labor induction was post-
term pregnancy in both groups (Table 1).
When the groups were analyzed in rela-
tion to the mean time between the beginning
of induction and the onset of labor, there was
a significant statistical difference. Labor (3
contractions per 10 minutes) started on aver-
Table 1. Characteristics of women and conditions indicating
labor induction according to the assigned treatment (in %)
Characteristics Misoprostol (105) Oxytocin (105) χ2 p value
Age < 25 years 58.1 52.4 0.48 0.49
White 68.6 75.2 0.85 0.36
Married 46.7 60.0 3.23 0.07
Family income < 4 mw* 52.4 59.0 0.03 0.87
Nulliparous 61.9 51.4 1.94 0.16
Up to 5 prenatal visits 24.8 38.1 2.27 0.13
Initial Bishop ≤ 3 76.2 82.8 1.05 0.30
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age within 253 minutes in the misoprostol
group, versus 352 minutes in the oxytocin
group. Regarding the time interval from the
start of induction to the occurrence of vagi-
nal delivery, there was also a significant dif-
ference. The mean time for this interval was
shorter for the misoprostol group (Table 2).
Table 2. Time interval for latent period and vaginal delivery
occurrence according to the labor induction method
Time interval Misoprostol Oxytocin p value
Latent period (minutes) 252.9 ± 149.1 352.3 ± 151.9 < 0.0001
N 104 92
Time from induction to vaginal delivery (hours) 10.6 ± 4.4 14.8 ± 5.1 < 0.0001
N 85 67
All values are means ± standard deviation (SD).
Table 4. Occurrence of tachysystole, hyperstimulation syndrome and
hypoxia, according to the drug used for labor induction
Misoprostol Oxytocin Risk 95% confidence
ratio  interval
Tachysystole 27 09 3.00 1.49 – 6.05
Hyperstimulation syndrome 03 04 0.94 0.22 – 4.07
Hypoxia 14 10 1.19 0.82 – 1.72
Figure 1. Distribution of the labor induction success rate, according to the method used.
In the misoprostol group, 81% of women
delivered vaginally within 24 hours from the
start of induction and the same occurred for
62% in the oxytocin group. When induction
success within the first 12 or 18 hours was
evaluated, the percentage was significantly
higher for the misoprostol group. Vaginal de-
livery occurred in 81% of the women in the
misoprostol group versus 64% in the oxytocin
group, which was also a significant difference
(Table 3). Using misoprostol for cervical rip-
ening and labor induction represented a 47%
reduction in the risk of having a cesarean sec-
tion (risk ratio = 0.53) and this also repre-
sented the fact that almost 6 cases would have
to be treated with misoprostol instead of oxy-
tocin in order to avoid one cesarean section
(number needed to treat = 5.8).
In the oxytocin group there were 13 cases
of failed induction while in the misoprostol
group there was only one. When prevalence
of abnormal uterine contractions between the
groups was analyzed, tachysystole was more
prevalent in the misoprostol group, with sta-
tistical significance: there were 27 cases in the
misoprostol group versus 9 in the oxytocin
group. Prevalence of fetal hypoxia was higher
in the misoprostol group. There were 14 cases
in the misoprostol group versus 10 in the oxy-
tocin group, presenting no statistical signifi-
cance (Table 4).
Among all the newborns, there were 43
cases of neonatal morbidity (evaluated
through their admission to the intensive care
unit, number of days of hospitalization and
respiratory alterations), 21 in the misoprostol
group and 22 in the oxytocin group, which
presented no significant difference. When
Apgar Index < 7 at the fifth minute of life
was analyzed, one case in the misoprostol
group and 2 in the oxytocin group were
found, again presenting no statistical signifi-
cance. The survival analysis showed that the
period from the beginning of induction un-
til vaginal delivery was significantly shorter
in the misoprostol group (Figure 1).
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
DISCUSSION
This study showed that a vaginal 25 µg
dose of misoprostol at four-hourly intervals
might be a more effective agent than oxytocin
for cervix ripening and labor induction, for
term and post-term pregnant women with
unripe cervices.
The present study showed that the aver-
age time interval to the onset of labor and also
to the occurrence of vaginal delivery was sig-
nificantly shorter in the misoprostol group.
These same results have also been found by
many other authors.2,11 Campos et al.2 stud-
ied misoprostol (50 µg, single dose, vaginally)
and oxytocin (2 to 32 mU/min) and found
an average of 552 min to the beginning of
labor for the misoprostol group, versus 745
min for the oxytocin group, presenting statis-
Table 3. Type of delivery according to the drug used for induction
Type of delivery Misoprostol Oxytocin
Vaginal (total) 85 (81%) 67 (64%)
Vaginal within 12 h 65 (62%) 26 (25%)
Vaginal within 18 h 78 (74%) 45 (43%)
Vaginal within 24 h 85 (81%) 67 (64%)
Cesarean section 20 (19%) 38 (36%)
Total (n) 105 105
χ2= 6.88; p = 0.008; risk ratio for cesarean section = 0.53; 95% confidence interval (0.33 – 0.84); number needed to treat = 5.8 (5.1 – 6.5).
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tical significance. These findings are consist-
ent with our results.
An American study3 demonstrated that
the average time interval until the occurrence
of vaginal delivery was also shorter for
misoprostol (50 µg at four-hourly intervals)
than for oxytocin (11 hours versus 18), pre-
senting statistical significance. In Turkey, an-
other study showed the same result, present-
ing quite similar averages when compared to
this study (9 hours versus 15).11
The average differences in these intervals
are related to the dose, route and administra-
tion interval. There are also some studies on
pregnant women with favorable cervices for
induction or previous administration of
dinoprostone before the start of induction.3,11
Some comparative studies between these
two drugs have shown that the incidence of
cesarean sections is higher in the oxytocin
group,2-5 and this was also shown in our in-
vestigation: the rate was almost doubled for
the oxytocin group. Other authors have found
higher rates in the misoprostol group, giving
statistical significance. Such occurrences might
be explained by higher doses and/or shorter
administration intervals, which may be asso-
ciated with a higher incidence of abnormal
uterine contractility and meconium.1,2
In our study, there were 14 cases of failed
induction, 13 of them in the oxytocin group,
showing a statistically significant difference
between the groups. This was also found in
the study by Kadanali et al.11
Our study showed no differences between
the groups regarding Apgar index at the fifth
minute of life and perinatal results. The ma-
jority of studies have shown that when peri-
natal results are evaluated by means of Apgar
score, cord pH, admission to intensive care
unit, number of days of hospitalization, meco-
nium passage syndrome or hyperbiliru-
binemia, there are no differences between the
groups, which confirms the findings of the
present study.2,4,11
In relation to uterine hypercontractility,
only tachysystole was different between the
groups: it was more prevalent in the
misoprostol group. However, there is disagree-
ment between studies concerning uterine
hypercontractility. Some studies report greater
incidence of uterine hypertonus and hypers-
timulation syndrome.1,4
Again, the hypothesis is that the dose, in-
terval and administration route are involved
in this response. Moreover, it is inferred that
the tachysystole occurring with the use of
misoprostol does not involve alterations in
fetal vitality, because uterine tonus does not
change. This was shown in the study by
Campos at al.,2 which monitored the intra-
uterine pressure in some women and found
that the average intensity of the contractions
and the uterine tonus did not differ between
the two groups (misoprostol versus oxytocin).
The findings of alterations in uterine
contractility and possible undesirable effects
on the fetus have been leading researchers to
perform more studies to check that the use of
misoprostol does not necessarily imply the
occurrence of hyperstimulation syndrome.
Such a need was emphasized in the latest sys-
tematic update review published in the
Cochrane Library.14
The first investigation done by Wing et al.1
was based on the same dose and administra-
tion interval as previously used by Sanchez-
Ramos (1993).3 There was significantly higher
incidence of tachysystole and meconium pas-
sage syndrome with misoprostol (50 µcg every
3 hours) than with dinoprostone. A second
study was performed by Wing et al.20, with the
modification of the dose to 25 µg every 3 hours,
and even though the high incidence of tachy-
systole persisted, it was not associated with a
significant increase in adverse neonatal results.
With these conclusions, these same au-
thors made a third study, attempting to find
the best dose interval for minimizing the con-
tractile problem. They compared 25 µg of
misoprostol every 3 hours with a six-hour in-
terval and concluded that the three-hour pro-
tocol was better in relation to the shorter time
interval until vaginal delivery. Less oxytocin
was needed and there was a lower incidence
of induction failure. They also observed that
tachysystole took place on average 4.4 hours
after the first dose in the three-hour protocol
group, suggesting the need for evaluation of
this administration interval.10
These clinical findings are in conformity
with reported time intervals for serum level
maintenance for misoprostol administered by
the vaginal route, in studies on its pharma-
cokinetics.12 This is exactly what was per-
formed in this study: the evaluation of
misoprostol for labor induction with a dose
of 25 µg every 4 hours.
Limitations do exist in this study. It could
not be carried out in a double-blind way, for
obvious reasons (the application of the two meth-
ods differ), which may have caused a bias. Al-
though physicians evaluating the patients dur-
ing labor may have been aware of the patient’s
group, it is unlikely that the outcomes from the
study would have been affected by this. Another
limitation is that the dose and administration
interval were empirical, based on the experience
of other authors. In spite of this, the results from
this study are quite favorable towards the use of
misoprostol as a modifying agent of the cervix
and for inducing labor.
However, there is still a lot to learn about
misoprostol and its use in obstetrics. It is not
known whether lower doses or a single dose
would produce the same effect. Should the first
dose be vaginal (to act directly on cervix ripen-
ing) and, if necessary, the next ones be admin-
istered orally?8 Do ethnic and metabolic differ-
ences in populations influence the dose used?
On the basis of published studies, it needs
to be decided when and under what circum-
stances misoprostol should be used. In cases of
unripe cervices, the use of misoprostol could
produce several beneficial effects, particularly
a decrease in the incidence of cesarean sections.
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CONCLUSIONS
This study shows favorable results regard-
ing the use of misoprostol as a modifying
agent of the cervix and for inducing labor.
Investigations need to be continued, in or-
der to find the smallest useful dose that fa-
cilitates cervix ripening and labor induction
without causing any uterine contractility al-
teration or harm to the fetus.
Sao Paulo Med J 2003; 121(3):102-106.
São Paulo Medical Journal — Revista Paulista de Medicina106
CONTEXTO: Na atualidade, misoprostol, um
metilanálogo sintético da prostaglandina E1,
vem recebendo atenção como um agente
maturador do colo e indutor do trabalho de
parto. No entanto, ainda é necessário
determinar melhor sua segurança e eficácia.
OBJETIVO: Comparar misoprostol intravaginal
versus ocitocina intravenosa para
amadurecimento cervical e indução de parto
em mulheres com colo uterino desfavorável.
TIPO DE ESTUDO: Ensaio clínico controlado
aleatorizado.
LOCAL: Hospital e Maternidade Leonor Mendes
de Barros, em São Paulo, SP, no período de
novembro de 1998 a dezembro de 2000.
PARTICIPANTES: 210 gestantes com
membranas íntegras e indicação para indução
do parto.
PROCEDIMENTOS: As mulheres, após a
aleatorização, receberam misoprostol vaginal
na dose de 25 µg a cada quatro horas, não
excedendo oito doses (105 mulheres) ou
ocitocina em uma infusão contínua (105
mulheres).
VARIÁVEIS ESTUDADAS: Período de
latência, tempo da indução ao parto vagi-
nal, tipo de parto, ocorrência de parto vagi-
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RESUMO
nal em função do tempo, ocorrência de
alterações do tônus uterino, hipóxia e
morbidade neonatal. Para verificar a
significância estatística das diferenças entre
os grupos, utilizaram-se os testes de qui -
quadrado, log-rank e t de Student.
RESULTADOS: Não houve diferença
significativa entre os grupos referentes às
indicações de indução, idade, paridade, raça,
renda familiar, índice inicial de Bishop e
número de consultas de pré-natal. A
incidência de cesárea, o período de latência e
o período da indução ao parto vaginal foram
significativamente menores para o grupo de
misoprostol. Das alterações do tônus uterino,
a taquissistolia foi significativamente mais
comum no grupo do misoprostol, entretanto
hipóxia e morbidade neonatal não foram
diferentes entre os grupos.
CONCLUSÃO: 25 µg de misoprostol vaginal
usados a cada quatro horas é seguro e mais
eficiente para o amadurecimento cervical e
indução do trabalho de parto do que a
ocitocina.
PALAVRAS-CHAVE: Misoprostol. Ocitocina.
Prostaglandinas. Indução. Parto. Ensaio.
Clínico. Controlado. Aleatorizado.
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